Results 61 to 70 of about 547,171 (369)

Osteocytes and the pathogenesis of hypophosphatemic rickets

Frontiers in Endocrinology, 2022
Since phosphorus is a component of hydroxyapatite, its prolonged deprivation affects bone mineralization. Fibroblast growth factor 23 (FGF23) is essential for maintaining phosphate homeostasis and is mainly produced by osteocytes.
Miwa Yamazaki, Toshimi Michigami
doaj   +1 more source

A Review of the Potential Application of Osteocyte-Related Biomarkers, Fibroblast Growth Factor-23, Sclerostin, and Dickkopf-1 in Predicting Osteoporosis and Fractures

Diagnostics, 2020
Bone turnover markers (BTMs) derived from the secretory activities of osteoblasts and the matrix-degrading activities of osteoclasts are useful in monitoring the progression of osteoporosis and the efficacy of anti-osteoporotic treatment.
Fitri Fareez Ramli, K. Chin
semanticscholar   +1 more source

Estimated glomerular filtration rate is a poor predictor of the concentration of middle molecular weight uremic solutes in chronic kidney disease [PDF]

, 2012
Background: Uremic solute concentration increases as Glomerular Filtration Rate (GFR) declines. Weak associations were demonstrated between estimated GFR (eGFR) and the concentrations of several small water-soluble and protein-bound uremic solutes ...
Barreto, Daniela V, Barreto, Fellype C, Eloot, Sunny, Glorieux, Griet, Lemke, Horst D, Lenglet, Aurélie, Liabeuf, Sophie, Massy, Ziad A, Neirynck, Nathalie, Vanholder, Raymond   +9 more
core   +8 more sources

Fibroblast growth factor 23—Klotho and hypertension: experimental and clinical mechanisms

Pediatric nephrology (Berlin, West), 2020
Hypertension (HTN) and chronic kidney disease (CKD) are increasingly recognized in pediatric patients and represent risk factors for cardiovascular morbidity and mortality later in life.
M. Freundlich, G. Gamba, B. Rodriguez-Iturbe   +2 more
semanticscholar   +1 more source

Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.

Journal of the American Medical Association (JAMA), 2011
CONTEXT A high level of the phosphate-regulating hormone fibroblast growth factor 23 (FGF-23) is associated with mortality in patients with end-stage renal disease, but little is known about its relationship with adverse outcomes in the much larger ...
T. Isakova, Huiliang Xie, Wei Yang, D. Xie, A. Anderson, J. Scialla, P. Wahl, O. Gutiérrez, S. Steigerwalt, Jiang He, S. Schwartz, J. Lo, A. Ojo, J. Sondheimer, Chi-yuan Hsu, J. Lash, M. Leonard, J. Kusek, H. Feldman, M. Wolf   +19 more
semanticscholar   +1 more source

Intravenous phosphate loading increases fibroblast growth factor 23 in uremic rats. [PDF]

PLoS ONE, 2014
Oral phosphate loading and calcitriol stimulate Fibroblast growth factor 23 (FGF23) secretion, but the mechanisms underlying the stimulation of FGF23 remain to be studied.
Noriko Arai-Nunota, Masahide Mizobuchi, Hiroaki Ogata, Ai Yamazaki-Nakazawa, Chiaki Kumata, Fumiko Kondo, Nozomu Hosaka, Fumihiko Koiwa, Eriko Kinugasa, Takanori Shibata, Tadao Akizawa   +10 more
doaj   +1 more source

Effect of intravenous iron on endogenous erythropoietin and FGF-23 secretion in patients with chronic kidney disease

Renal Failure, 2023
Introduction It has been observed that intravenous iron administration may suppress endogenous production of erythropoietin (EPO). We postulate that this effect may be mediated by increased FGF-23 secretion.Aim of the study To evaluate the short-term ...
Katarzyna Muras-Szwedziak, Ewa Pawłowicz-Szlarska, Michał Nowicki   +2 more
doaj   +1 more source

The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia

International Journal of Molecular Sciences, 2019
In patients with chronic kidney disease (CKD), adverse outcomes such as systemic inflammation and anemia are contributing pathologies which increase the risks for cardiovascular mortality.
Brian Czaya, C. Faul
semanticscholar   +1 more source

Fibroblast growth factor 23: are we ready to use it in clinical practice?

JN. Journal of Nephrology (Milano. 1992), 2020
Patients with chronic kidney disease (CKD) have a greatly enhanced risk of cardiovascular morbidity and mortality. Over the past decade it has come clear that a disturbed calcium-phosphate metabolism, with Fibroblast Growth Factor-23 as a key hormone, is
Annet Bouma-de Krijger, M. Vervloet
semanticscholar   +1 more source

Fibroblast growth factor 23 and cardiovascular disease in patients with chronic kidney disease [PDF]

, 2018
Chronic kidney disease (CKD) has been known to be associated with an increased risk of cardiovascular (CV) mortality and morbidity in Japan. Although traditional risk factors contribute to the development of CV disease in CKD patients, they cannot fully ...
NITTA Kosaku
core   +2 more sources